For research use only. We do not sell to patients.
Ionizable lipids / 200Oi10
200Oi10 chemical structure
Product imageResearch use only
CAT. NO. DC60545Featured

200Oi10

Pack size & price

USD
TotalUS$650
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

200Oi10 is an ionizable lipidoid evaluated in a comparative mouse study of pancreatic mRNA delivery. Its reported activity depends on administration route and helper-lipid composition. The paper subsequently focuses on 306Oi10; those later macrophage-transfer, beta-cell and tolerability results are not evidence for 200Oi10.

Open full Formulation & Performance →

Literature evidence · DC60545

Formulation & Performance

200Oi10-specific results from Figures 1B and 2B, with the complete SI checked to prevent attribution of 306Oi10 results.

The 200Oi10 structure in SI Figure S1 was checked against the catalog connectivity. The catalog molecular weight and formula are retained; paper results are not batch release specifications.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
200Oi10DC605451277.01350.446953
DOPENot uniquely mapped744.03160.119045
CholesterolDCD-041386.6546.50.179792
C14-PEG2000 (source label)Not uniquely mappedNot established2.5Not calculable from disclosed data

This table is the IV/IP comparison composition. The separate helper-lipid comparison uses 35:40:22.5:2.5, with DOPE, PS or DOTAP. The source gives a 10:1 lipidoid:mRNA mass ratio. PEG-lipid exact identity/MW is not resolved from the source label, so DMG-PEG2000 is not substituted.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
200Oi10——
DOPE——
Cholesterol——
C14-PEG2000 (source label)——

Two formulation contexts

ExperimentLipid:helper:cholesterol:PEG molar ratioHelper lipidSource
Route comparison35:16:46.5:2.5DOPEMain Fig. 1B and Methods.
Helper-lipid comparison35:40:22.5:2.5DOPE, PS or DOTAP in separate groupsMain Fig. 2B and Methods.
N/P reportingMethods state 7.8 for DOPE/PS and 8.8 for 40% DOTAP LNPsThese are reported method-level values, not recalculated product specifications.No 200Oi10-specific N/P calculation is inferred from 10:1 w/w.

Mouse reporter expression: 200Oi10 only

ComparisonFindingStudy context
Intraperitoneal vs intravenousIP delivery increased pancreatic reporter expression relative to IV in the compared formulations.Female C57BL/6 mice, luciferase mRNA 0.5 mg/kg; 3 h; n=3/group; main Fig. 1B.
DOPE vs PS vs DOTAPPancreatic signal was broadly similar across helpers, while DOTAP reduced off-target liver/spleen expression.Same RNA dose and 3 h endpoint; main Fig. 2B.
Overall expression200Oi10 generated the lowest overall luminescent signal among the lipidoids in the helper comparison.Main results text. A greater pancreatic fraction is not necessarily a greater absolute pancreatic signal.
Exact pancreatic percentageNot assigned.Previously cited secondary figure-derived percentages are not treated as exact primary-source measurements.

What this paper does not establish for 200Oi10

TopicEvidence boundary
Macrophage-mediated transfer and beta-cell expressionLater experiments followed 306Oi10 with DOTAP; not assigned to 200Oi10.
Disease-model efficacy and tolerabilityLater efficacy/safety outcomes belong to the selected follow-up formulation, not automatically all screened lipidoids.
Particle size, PDI, encapsulation and pKaNo target-specific numerical record established for 200Oi10 in the reviewed main/SI.
Original figuresFigures 1 and 2 contain all three lipid groups. For this product, read panel B; other panels are comparators.

Original study figures

Figure 1: Route comparison; 200Oi10 is panel B
Figure 1: Route comparison; 200Oi10 is panel B
Melamed et al. (2023), Figure 1. Original, unmodified figure. Panel B is 200Oi10; panels A and C represent other lipidoids. Full caption at source. Original source and caption · CC BY 4.0
Figure 2: Helper comparison; 200Oi10 is panel B
Figure 2: Helper comparison; 200Oi10 is panel B
Melamed et al. (2023), Figure 2. Original, unmodified figure. Panel B is 200Oi10; other lipidoids are shown for study context. Full caption at source. Original source and caption · CC BY 4.0

References and source locations

  1. Melamed JR et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic beta cells via macrophage-mediated gene transfer. Science Advances 9, eade1444 (2023). DOI: 10.1126/sciadv.ade1444.
  2. Complete supporting information: Figure S1 and Figures S3-S8; main Figures 1B and 2B define the target-specific evidence.
CAS No.Not available
Chemical Name200Oi10
Synonyms200,Oi,10, 200Oi,10
SMILESCC(C)CCCCCCCOC(=O)CCN(CCC(=O)OCCCCCCCC(C)C)CCN(CCC(=O)OCCCCCCCC(C)C)CCN1CCN(CCN(CCC(=O)OCCCCCCCC(C)C)CCC(=O)OCCCCCCCC(C)C)CC1
FormulaC75H145O10N5
M.Wt1,277.01
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Melamed JR et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic beta cells via macrophage-mediated gene transfer. Science Advances 9, eade1444 (2023). DOI: 10.1126/sciadv.ade1444.
  2. Complete supporting information: Figure S1 and Figures S3-S8; main Figures 1B and 2B define the target-specific evidence.
F&PFormulation & PerformanceComposition, study results and referencesRead online →
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg7.8308 mL1.5662 mL783.08 μL
25 mg19.5770 mL3.9154 mL1.9577 mL
50 mg39.1540 mL7.8308 mL3.9154 mL
100 mg78.3079 mL15.6616 mL7.8308 mL
250 mg195.7698 mL39.1540 mL19.5770 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.